Sponsor: Immix Biopharma, Inc. (IMMX). Review status: Immix Biopharma announced an interim update across all NEXICART-2 patients on September 29, 2026: an 89% complete response rate (8-K exhibit 99.1). Interim data, not a final readout. We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
NXC-201's most recent tracked catalyst has already reported: positive data on Sep 29, 2026, per the company's own release (linked in the history below). No further catalyst is on our calendar yet.
What happened at NXC-201's most recent FDA decision?
No FDA decision for NXC-201 is in our archive yet.
Who makes NXC-201?
Immix Biopharma, Inc. (IMMX).
Where does this data come from?
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.
Facts and dates only; not investment advice. Verify against primary FDA, SEC
and company filings. pdufa.bio is not affiliated with the FDA.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.